Janux Therapeutics, Inc.
JANX
$29.69
$1.003.49%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -71.93% | -142.56% | 65.96% | 15.46% | 26.81% |
| Total Depreciation and Amortization | -3.58% | 2.00% | 7.43% | 17.44% | 31.76% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 37.24% | 411.84% | -23.93% | 1.13% | -16.86% |
| Change in Net Operating Assets | 68.52% | 516.39% | -338.40% | -535.29% | -231.10% |
| Cash from Operations | -68.92% | 80.95% | 33.43% | -6.66% | 16.89% |
| Capital Expenditure | 91.84% | 94.68% | 83.62% | 30.88% | 74.95% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 191.87% | 120.82% | -1,133.87% | -1,242.86% | 2,474.78% |
| Cash from Investing | 205.01% | 120.62% | -1,167.95% | -1,201.33% | 793.45% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 46,428.28% | -97.09% | 423.67% | 20,290.57% | 335.08% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 46,428.28% | -97.09% | 423.67% | 20,290.57% | 335.08% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 19,571.26% | 173.06% | -6,018.19% | 1,018.79% | 115.41% |